FDA grants priority review for HIF-2α inhibitor belzutifan (MK-6482)
The US Food and Drug Administration (FDA) has granted priority review for a marketing license for the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, belzutifan. Belzutifan is a new medicine for the treatment of patients with von Hippel-Lindau (VHL) renal cell carcinoma (RCC) who do not need surgery immediately. Kidney cancers frequently have mutations in a gene called the […]